$ARIA Announces Data Presentations at the European Hematology Association

0
576

ARIAD Announces Data Presentations at the European Hematology Association (EHA) Congress

ARIAD Pharmaceuticals, Inc. (ARIA) today announced that clinical data on Iclusig® (ponatinib) will be presented at the 20th conference of the European Hematology Association (EHA) being held in Vienna, Austria, June 11 to 14, 2015.

The schedule and meeting location for the sessions, together with the abstract information, are listed below:

Title:

Ponatinib Efficacy and Safety in Heavily Pretreated Leukemia Patients: 3-Year Results of the PACE Trial

Abstract No: P234
Presenter: Jorge Cortes, M.D., (The University of Texas MD Anderson Cancer Center, Houston, US)
Poster Session: Chronic myeloid leukemia – Clinical 1
Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST)
Location: Poster Area, Hall C
Title:

Long-Term Follow-up of Ponatinib Efficacy and Safety in Patients (Pts) with the T315I Mutation in the Phase 1 and Phase 2 (PACE) Trials

Abstract No: P236
Presenter: Michele Baccarani, M.D., (University of Bologna, Italy)
Poster Session: Chronic myeloid leukemia – Clinical 1
Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST)
Location: Poster Area, Hall C
Title:

Minimum Follow-up of 4 Years for Ongoing Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Phase 1 Trial of Ponatinib

Abstract No: P237
Presenter: Moshe Talpaz, M.D., (University of Michigan Medical Center, Ann Arbor, US)
Poster Session: Chronic myeloid leukemia – Clinical 1
Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST)
Location: Poster Area, Hall C
Title:

Responses at Early Landmark Time Points are Associated with Outcomes in Heavily Pretreated CP-CML Patients (Pts) Treated with Ponatinib

Abstract No: P235
Presenter: Martin C. Müller, M.D. (Medical Clinic, University Hospital Mannheim, Mannheim, Germany)
Poster Session: Chronic myeloid leukemia – Clinical 1
Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST)
Location: Poster Area, Hall C
Title:

A Model-Based Assessment of the Benefits and Risks of Ponatinib Versus Bosutinib in Third-Line Treatment of Chronic Myeloid Leukemia (CP-CML)

Abstract No: P424
Presenter: Shannon Cartier, M.D., (Optum, Burlington, Canada)
Oral Session: Quality of life, palliative care, ethics and health economics
Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST)
Location: Poster Area, Hall C

About Iclusig® (ponatinib) tablets

Iclusig is approved in the U.S., EU, Switzerland, Australia, Israel and Canada. Iclusig is a kinase inhibitor indicated in the EU for adult patients with:

  • chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation
  • Philadelphia chromosome positive acute lymphoblastic leukaemia (PH+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visithttp://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

Iclusig® is a registered trademark of ARIAD Pharmaceuticals, Inc.

Contact:
ARIAD Pharmaceuticals
For Investors
Kendra Adams, 617-503-7028
[email protected]
or
For U.S. Media
Liza Heapes, 617-621-2315
[email protected]
or
For EU Media
Gemma White, +44 (0)20 337 25 221
[email protected]

LEAVE A REPLY

Please enter your comment!
Please enter your name here